Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
GSK-598809. GSK-598809 is a selective dopamine D 3 receptor antagonist that is or was under development for the treatment of substance-related disorders, smoking withdrawal, and eating disorders like binge eating disorder. [1][2][3][4] The drug is highly selective for the dopamine D 3 receptor (K i = 6.2 nM) over the dopamine D 2 receptor (K i ...
Download QR code; Wikidata item; Print/export Download as PDF; Printable version; In other projects ... Pages in category "Drugs developed by GSK plc"
Some countries have faulted Turkey for funding Islamist rebel groups in Syria, including al-Qaeda's affiliate in Syria, the al-Nusra Front. [12] [13] In October 2014, U.S. Vice President Joe Biden said that Turkey, Saudi Arabia and the UAE had "poured hundreds of millions of dollars and tens of thousands of tons of weapons into anyone who would fight against Al-Assad".
Manufacturing companies based in London. Multinational companies headquartered in England. Pharmaceutical companies of England. Vaccine producers.
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase that mediates the addition of phosphate molecules onto serine and threonine amino acid residues. First discovered in 1980 as a regulatory kinase for its namesake, glycogen synthase (GS), [2] GSK-3 has since been identified as a protein kinase for over 100 different proteins in a variety of different pathways.
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.